Home > Gtc Biotherapeutics Salary

Gtc Biotherapeutics Salary

  • 33
  • 13
  • 68
Gtc Biotherapeutics average salary is $52,879, median salary is $48,000 with a salary range from $34,070 to $76,565.
Gtc Biotherapeutics salaries are collected from government agencies and companies. Each salary is associated with a real job position. Gtc Biotherapeutics salary statistics is not exclusive and is for reference only. They are presented "as is" and updated regularly.
Total 3 Gtc Biotherapeutics Salaries. Sorted by Date, page 1
Ranked By:
Job Title Salaries City Year More info
Accounting Supervisor 48,000-48,000 Alhambra, CA, 91801 2015 Gtc Biotherapeutics Accounting Supervisor Salaries (1)
Gtc Biotherapeutics Alhambra, CA Salaries
Market Analyst 34,070-34,070 Alhambra, CA, 91801 2013 Gtc Biotherapeutics Market Analyst Salaries (1)
Gtc Biotherapeutics Alhambra, CA Salaries
Financial Manager 76,565-76,565 Alhambra, CA, 91801 2012 Gtc Biotherapeutics Financial Manager Salaries (1)
Gtc Biotherapeutics Alhambra, CA Salaries
Calculate how much you could earn

It's FREE. Based on your input and our analysis.     How we do it?

All fields are required for calculation accuracy.

  • We will send you an email to access your personalized report.
  • We won’t share your email address

Gtc Biotherapeutics salary is full-time annual starting salary. Intern, contractor and hourly pay scale vary from regular exempt employee. Compensation depends on work experience, job location, bonus, benefits and other factors.

Real Jobs Salary - Salary List
Calculate Your Salary Ranking
Gtc Biotherapeutics Jobs
See more Gtc Biotherapeutics Jobs»
Search All Jobs

JobsOpenHiring – Find open jobs faster
Gtc Biotherapeutics... Information
  • GTC Biotherapeutics, Inc.
  • Industry: Biotech/Healthcare
  • City: Framingham, MA
  • GTC Biotherapeutics is the leader in the development, production, and commercialization of therapeutic proteins through transgenic animal technology. GTC has more than a dozen programs in development, including its internal proprietary products, one of which is in clinical trials. GTC has begun a clinical efficacy study in Europe with its lead internal program, recombinant human antithrombin III (rhATIII), a human blood plasma protein.